Year-End Submissions Total 17, Including Four From Aventis
This article was originally published in Pharmaceutical Approvals Monthly
Aventis was the most prominent participant in the year-end NDA filing rush, submitting four applications: two new molecular entities, a vaccine and a new formulation.
You may also be interested in...
La Jolla initiates a Phase IV trial of its pending lupus agent Riquent (abetimus) to support full approval, the firm announces Aug. 2. The randomized, double-blind, placebo-controlled study was agreed to under the special protocol assessment process and will meet FDA's accelerated approval requirement for a confirmatory postmarketing study. La Jolla said the trial design has "several enhancements" compared to prior Riquent studies, "including twice as many patients receiving Riquent compared with placebo, increased patient enrollment of approximately 500 to 600 patients, more control of immunosuppressive drugs at baseline, higher doses of Riquent in some treatment groups, and 12-month treatment duration for each patient." The primary endpoint is time to renal flare. The study will continue for "several years." Riquent's PDUFA date is Oct. 16 (1Pharmaceutical Approvals Monthly Jan 1, 2004, p. 15)...
Aventis and Altana are hoping Alvesco’s similar rate of oropharyngeal side effects to placebo will help the agent penetrate the inhaled corticosteroid market.
Genta’s Phase III Genasense results should be enough to gain FDA approval for treatment of malignant melanoma despite the lack of a statistically significant improvement in survival in the intent to treat population, the firm told a Sept. 10 conference call.